《PNAS,9月22日,A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants》

  • 来源专题:COVID-19科研动态监测
  • 编译者: zhangmin
  • 发布时间:2020-10-14
  • A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants
    View ORCID ProfileBethany Dearlove,  View ORCID ProfileEric Lewitus,  View ORCID ProfileHongjun Bai,  View ORCID ProfileYifan Li,  View ORCID ProfileDaniel B. Reeves,  View ORCID ProfileM. Gordon Joyce, Paul T. Scott,  View ORCID ProfileMihret F. Amare,  View ORCID ProfileSandhya Vasan,  View ORCID ProfileNelson L. Michael,  View ORCID ProfileKayvon Modjarrad, and  View ORCID ProfileMorgane Rolland
    PNAS September 22, 2020 117 (38) 23652-23662; first published August 31, 2020; https://doi.org/10.1073/pnas.2008281117
    Edited by John M. Coffin, Tufts University, Boston, MA, and approved July 25, 2020 (received for review April 30, 2020)

    Abstract
    The magnitude of the COVID-19 pandemic underscores the urgency for a safe and effective vaccine. Many vaccine candidates focus on the Spike protein, as it is targeted by neutralizing antibodies and plays a key role in viral entry. Here we investigate the diversity seen in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequences and compare it to the sequence on which most vaccine candidates are based. Using 18,514 sequences, we perform phylogenetic, population genetics, and structural bioinformatics analyses. We find limited diversity across SARS-CoV-2 genomes: Only 11 sites show polymorphisms in >5% of sequences; yet two mutations, including the D614G mutation in Spike, have already become consensus. Because SARS-CoV-2 is being transmitted more rapidly than it evolves, the viral population is becoming more homogeneous, with a median of seven nucleotide substitutions between genomes. There is evidence of purifying selection but little evidence of diversifying selection, with substitution rates comparable across structural versus nonstructural genes. Finally, the Wuhan-Hu-1 reference sequence for the Spike protein, which is the basis for different vaccine candidates, matches optimized vaccine inserts, being identical to an ancestral sequence and one mutation away from the consensus. While the rapid spread of the D614G mutation warrants further study, our results indicate that drift and bottleneck events can explain the minimal diversity found among SARS-CoV-2 sequences. These findings suggest that a single vaccine candidate should be efficacious against currently circulating lineages.

  • 原文来源:https://www.pnas.org/content/117/38/23652
相关报告
  • 《PNAS,9月22日,Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-10-14
    • Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis Diana Buitrago-Garcia , Dianne Egli-Gany , Michel J. Counotte , Stefanie Hossmann, Hira Imeri, Aziz Mert Ipekci, Georgia Salanti, Nicola Low Published: September 22, 2020https://doi.org/10.1371/journal.pmed.1003346 Abstract Background There is disagreement about the level of asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We conducted a living systematic review and meta-analysis to address three questions: (1) Amongst people who become infected with SARS-CoV-2, what proportion does not experience symptoms at all during their infection? (2) Amongst people with SARS-CoV-2 infection who are asymptomatic when diagnosed, what proportion will develop symptoms later? (3) What proportion of SARS-CoV-2 transmission is accounted for by people who are either asymptomatic throughout infection or presymptomatic? Methods and findings We searched PubMed, Embase, bioRxiv, and medRxiv using a database of SARS-CoV-2 literature that is updated daily, on 25 March 2020, 20 April 2020, and 10 June 2020. Studies of people with SARS-CoV-2 diagnosed by reverse transcriptase PCR (RT-PCR) that documented follow-up and symptom status at the beginning and end of follow-up or modelling studies were included. One reviewer extracted data and a second verified the extraction, with disagreement resolved by discussion or a third reviewer. Risk of bias in empirical studies was assessed with an adapted checklist for case series, and the relevance and credibility of modelling studies were assessed using a published checklist. We included a total of 94 studies.
  • 《Science,9月25日,Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-10-14
    • Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy View ORCID ProfileHongjing Gu1,*, View ORCID ProfileQi Chen1,*, View ORCID ProfileGuan Yang2,*, View ORCID ProfileLei He1,*, View ORCID ProfileHang Fan1,*, View ORCID ProfileYong-Qiang Deng1,*, Yanxiao Wang2, Yue... Science  25 Sep 2020: Vol. 369, Issue 6511, pp. 1603-1607 DOI: 10.1126/science.abc4730 Abstract The ongoing coronavirus disease 2019 (COVID-19) pandemic has prioritized the development of small-animal models for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We adapted a clinical isolate of SARS-CoV-2 by serial passaging in the respiratory tract of aged BALB/c mice. The resulting mouse-adapted strain at passage 6 (called MASCp6) showed increased infectivity in mouse lung and led to interstitial pneumonia and inflammatory responses in both young and aged mice after intranasal inoculation. Deep sequencing revealed a panel of adaptive mutations potentially associated with the increased virulence. In particular, the N501Y mutation is located at the receptor binding domain (RBD) of the spike protein. The protective efficacy of a recombinant RBD vaccine candidate was validated by using this model. Thus, this mouse-adapted strain and associated challenge model should be of value in evaluating vaccines and antivirals against SARS-CoV-2.